{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:29:18Z","timestamp":1759796958252,"version":"build-2065373602"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.ijrobp.2020.06.012","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T16:50:25Z","timestamp":1602780625000},"page":"839-845","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Radiation for Cancers of the Uterine Corpus and Cervix: Incremental Steps, and Glimmers of the Future"],"prefix":"10.1016","volume":"108","author":[{"given":"Junzo","family":"Chino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shari","family":"Damast","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Kidd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Harkenrider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Albuquerque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell","family":"Kamrava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2020.06.012_bib1","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S1470-2045(19)30395-X","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): Patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial","volume":"20","author":"de Boer","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2020.06.012_bib2","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa1813181","article-title":"Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer","volume":"380","author":"Matei","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2020.06.012_bib3","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1200\/JCO.18.01575","article-title":"Phase III trial: Adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel\/carboplatin in high-intermediate and high-risk early stage endometrial cancer","volume":"37","author":"Randall","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2020.06.012_bib4","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ijrobp.2018.05.034","article-title":"Defining the place of adjuvant chemotherapy and radiation for high-risk endometrial cancer from recent randomized clinical trials: Some answers, more questions","volume":"102","author":"Albuquerque","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.06.012_bib5","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1200\/JCO.19.02381","article-title":"Improvement in patient-reported outcomes with intensity-modulated radiotherapy (RT) compared with standard RT: A report from the NRG Oncology RTOG 1203 study","volume":"38","author":"Yeung","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2020.06.012_bib6","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/s41416-018-0310-8","article-title":"Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: Improving patient selection for adjuvant therapy","volume":"119","author":"Wortman","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijrobp.2020.06.012_bib7","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/jamaoncol.2019.3857","article-title":"Sequential ipilimumab after chemoradiotherapy in curative-intent treatment of patients with node-positive cervical cancer","volume":"6","author":"Mayadev","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2020.06.012_bib8","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ygyno.2006.02.007","article-title":"Final analysis of RTOG 9708: Adjuvant postoperative irradiation combined with cisplatin\/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer","volume":"103","author":"Greven","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijrobp.2020.06.012_bib9","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(19)30416-4","article-title":"Management of high-risk endometrial cancer: Are we there yet?","volume":"20","author":"Randall","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2020.06.012_bib10","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ygyno.2019.06.020","article-title":"Defining the survival benefit of adjuvant pelvic radiotherapy and chemotherapy versus chemotherapy alone in stages III-IVa endometrial carcinoma","volume":"154","author":"Xiang","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijrobp.2020.06.012_bib11","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ygyno.2009.06.035","article-title":"Node-positive adenocarcinoma of the endometrium: Outcome and patterns of recurrence with and without external beam irradiation","volume":"115","author":"Klopp","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijrobp.2020.06.012_bib12","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.brachy.2017.07.002","article-title":"Salvage high-dose-rate brachytherapy and external beam radiotherapy for isolated vaginal recurrences of endometrial cancer with no prior adjuvant therapy","volume":"16","author":"Chapman","year":"2017","journal-title":"Brachytherapy"},{"key":"10.1016\/j.ijrobp.2020.06.012_bib13","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0039-6109(05)70172-9","article-title":"Surgical management of advanced or recurrent endometrial cancer","volume":"81","author":"Chi","year":"2001","journal-title":"Surg Clin North Am"},{"key":"10.1016\/j.ijrobp.2020.06.012_bib14","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1097\/IGC.0b013e3182915c20","article-title":"Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel\/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009","volume":"23","author":"Makker","year":"2013","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijrobp.2020.06.012_bib15","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ijrobp.2020.06.012_bib16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ygyno.2019.01.007","article-title":"Association of chemotherapy and radiotherapy sequence with overall survival in locoregionally advanced endometrial cancer","volume":"153","author":"Goodman","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijrobp.2020.06.012_bib17","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ygyno.2015.01.546","article-title":"Sequential versus \u201csandwich\u201d sequencing of adjuvant chemoradiation for the treatment of stage iii uterine endometrioid adenocarcinoma","volume":"137","author":"Lu","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijrobp.2020.06.012_bib18","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S1470-2045(16)30120-6","article-title":"Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): An open-label, multicentre, randomised, phase 3 trial","volume":"17","author":"de Boer","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2020.06.012_bib19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1200\/JCO.2004.00.7617","article-title":"Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: A gynecologic oncology group study","volume":"24","author":"Randall","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2020.06.012_bib20","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/sj.bjc.6603279","article-title":"Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: Results of a randomised trial","volume":"95","author":"Maggi","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijrobp.2020.06.012_bib21","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1016\/j.ejca.2010.06.002","article-title":"Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer\u2014results from two randomised studies","volume":"46","author":"Hogberg","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2020.06.012_bib22","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ygyno.2007.09.025","article-title":"Pilot phase II trial of radiation \"sandwiched\" between combination paclitaxel\/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC)","volume":"108","author":"Fields","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijrobp.2020.06.012_bib23","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ygyno.2007.06.014","article-title":"The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer","volume":"107","author":"Alvarez Secord","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijrobp.2020.06.012_bib24","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ygyno.2009.03.027","article-title":"Adjuvant carboplatin and paclitaxel chemotherapy interposed with involved field radiation for advanced endometrial cancer","volume":"114","author":"Lupe","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijrobp.2020.06.012_bib25","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ygyno.2010.12.338","article-title":"A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a \"sandwich\" method for stage III, IV, and recurrent endometrial cancer","volume":"121","author":"Geller","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijrobp.2020.06.012_bib26","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1158\/1078-0432.CCR-15-2878","article-title":"Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts","volume":"22","author":"Stelloo","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2020.06.012_bib27","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/cncr.31901","article-title":"Mismatch repair deficiency identifies patients with high-intermediate-risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: A prognostic biomarker","volume":"125","author":"Backes","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2020.06.012_bib28","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ygyno.2019.03.097","article-title":"Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer","volume":"154","author":"Reijnen","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijrobp.2020.06.012_bib29","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1200\/JCO.2016.67.8722","article-title":"Clinicopathologic significance of mismatch repair defects in endometrial cancer: An NRG Oncology\/Gynecologic Oncology Group study","volume":"34","author":"McMeekin","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2020.06.012_bib30","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ijrobp.2020.06.012_bib31","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.ijrobp.2019.03.038","article-title":"Change in patterns of failure after image-guided brachytherapy for cervical cancer: Analysis from the retroembrace study","volume":"104","author":"Tan","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.06.012_bib32","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1200\/JCO.2009.25.9663","article-title":"Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIb to IVa carcinoma of the cervix","volume":"29","author":"Duenas-Gonzalez","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301620312530?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301620312530?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T09:56:44Z","timestamp":1759744604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301620312530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0360301620312530"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2020.06.012","relation":{},"ISSN":["0360-3016"],"issn-type":[{"type":"print","value":"0360-3016"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiation for Cancers of the Uterine Corpus and Cervix: Incremental Steps, and Glimmers of the Future","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2020.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}